U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Classic Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder

MedGen UID:
1682426
•Concept ID:
C5190713
•
Neoplastic Process
Synonyms: Classic Hodgkin Lymphoma PTLD; Classic Hodgkin Lymphoma Type Post-Transplant Lymphoproliferative Disorder; Classic Hodgkin Lymphoma Type PTLD; Classical Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder; Classical Hodgkin Lymphoma Type Post-Transplant Lymphoproliferative Disorder; Classical Hodgkin lymphoma type post-transplant lymphoproliferative disorder; Classical Hodgkin lymphoma type posttransplant lymphoproliferative disorder; Classical Hodgkin Lymphoma Type PTLD; Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder; Hodgkin Lymphoma PTLD; Hodgkin's Lymphoma Post-Transplant Lymphoproliferative Disorder; Hodgkin's Lymphoma PTLD
SNOMED CT: Classical Hodgkin lymphoma type posttransplant lymphoproliferative disorder (782919005); Classical Hodgkin lymphoma type post-transplant lymphoproliferative disorder (782919005)

Definition

A lymphoproliferative disorder that fulfills the criteria for classic Hodgkin lymphoma and arises as a result of post-transplant immunosuppression therapy. It is most often seen in renal transplant patients. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVClassic Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder

Professional guidelines

PubMed

Treatment and outcomes in classic Hodgkin lymphoma post-transplant lymphoproliferative disorder in children.
Twist CJ, Hiniker SM, Gratzinger D, Gutkin PM, Merriott DJ, Iagaru A, Link MP, Donaldson SS
Pediatr Blood Cancer 2019 Aug;66(8):e27803. Epub 2019 May 7 doi: 10.1002/pbc.27803. PMID: 31062898

Recent clinical studies

Etiology

Post-transplant lymphoproliferative disorder after paediatric liver transplantation.
Liu Y, Sun LY, Zhu ZJ, Wei L, Qu W, Wang L, Yuan LL, Zeng ZG
Int J Clin Pract 2021 Apr;75(4):e13843. Epub 2020 Dec 14 doi: 10.1111/ijcp.13843. PMID: 33222369
Treatment and outcomes in classic Hodgkin lymphoma post-transplant lymphoproliferative disorder in children.
Twist CJ, Hiniker SM, Gratzinger D, Gutkin PM, Merriott DJ, Iagaru A, Link MP, Donaldson SS
Pediatr Blood Cancer 2019 Aug;66(8):e27803. Epub 2019 May 7 doi: 10.1002/pbc.27803. PMID: 31062898
Post-transplant lymphoproliferative disorders.
Singavi AK, Harrington AM, Fenske TS
Cancer Treat Res 2015;165:305-27. doi: 10.1007/978-3-319-13150-4_13. PMID: 25655616
Successful treatment of a classic Hodgkin lymphoma-type post-transplant lymphoproliferative disorder with tailored chemotherapy and Epstein-Barr virus-specific cytotoxic T lymphocytes in a pediatric heart transplant recipient.
Basso S, Zecca M, Calafiore L, Rubert L, Fiocchi R, Paulli M, Quartuccio G, Guido I, Sebastiani R, Croci GA, Beschi C, Nardiello I, Ginevri F, Cugno C, Comoli P
Pediatr Transplant 2013 Nov;17(7):E168-73. Epub 2013 Sep 1 doi: 10.1111/petr.12146. PMID: 23992468
Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations.
Jagadeesh D, Woda BA, Draper J, Evens AM
Curr Treat Options Oncol 2012 Mar;13(1):122-36. doi: 10.1007/s11864-011-0177-x. PMID: 22241590

Diagnosis

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Moskowitz AJ, Shah G, Schöder H, Ganesan N, Drill E, Hancock H, Davey T, Perez L, Ryu S, Sohail S, Santarosa A, Galasso N, Neuman R, Liotta B, Blouin W, Kumar A, Lahoud O, Batlevi CL, Hamlin P, Straus DJ, Rodriguez-Rivera I, Owens C, Caron P, Intlekofer AM, Hamilton A, Horwitz SM, Falchi L, Joffe E, Johnson W, Lee C, Palomba ML, Noy A, Matasar MJ, Pongas G, Salles G, Vardhana S, Sanin BW, von Keudell G, Yahalom J, Dogan A, Zelenetz AD, Moskowitz CH
J Clin Oncol 2021 Oct 1;39(28):3109-3117. Epub 2021 Jun 25 doi: 10.1200/JCO.21.01056. PMID: 34170745Free PMC Article
Post-transplant lymphoproliferative disorder after paediatric liver transplantation.
Liu Y, Sun LY, Zhu ZJ, Wei L, Qu W, Wang L, Yuan LL, Zeng ZG
Int J Clin Pract 2021 Apr;75(4):e13843. Epub 2020 Dec 14 doi: 10.1111/ijcp.13843. PMID: 33222369
Treatment and outcomes in classic Hodgkin lymphoma post-transplant lymphoproliferative disorder in children.
Twist CJ, Hiniker SM, Gratzinger D, Gutkin PM, Merriott DJ, Iagaru A, Link MP, Donaldson SS
Pediatr Blood Cancer 2019 Aug;66(8):e27803. Epub 2019 May 7 doi: 10.1002/pbc.27803. PMID: 31062898
Post-transplant lymphoproliferative disorders.
Singavi AK, Harrington AM, Fenske TS
Cancer Treat Res 2015;165:305-27. doi: 10.1007/978-3-319-13150-4_13. PMID: 25655616
Successful treatment of a classic Hodgkin lymphoma-type post-transplant lymphoproliferative disorder with tailored chemotherapy and Epstein-Barr virus-specific cytotoxic T lymphocytes in a pediatric heart transplant recipient.
Basso S, Zecca M, Calafiore L, Rubert L, Fiocchi R, Paulli M, Quartuccio G, Guido I, Sebastiani R, Croci GA, Beschi C, Nardiello I, Ginevri F, Cugno C, Comoli P
Pediatr Transplant 2013 Nov;17(7):E168-73. Epub 2013 Sep 1 doi: 10.1111/petr.12146. PMID: 23992468

Therapy

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Moskowitz AJ, Shah G, Schöder H, Ganesan N, Drill E, Hancock H, Davey T, Perez L, Ryu S, Sohail S, Santarosa A, Galasso N, Neuman R, Liotta B, Blouin W, Kumar A, Lahoud O, Batlevi CL, Hamlin P, Straus DJ, Rodriguez-Rivera I, Owens C, Caron P, Intlekofer AM, Hamilton A, Horwitz SM, Falchi L, Joffe E, Johnson W, Lee C, Palomba ML, Noy A, Matasar MJ, Pongas G, Salles G, Vardhana S, Sanin BW, von Keudell G, Yahalom J, Dogan A, Zelenetz AD, Moskowitz CH
J Clin Oncol 2021 Oct 1;39(28):3109-3117. Epub 2021 Jun 25 doi: 10.1200/JCO.21.01056. PMID: 34170745Free PMC Article
Post-transplant lymphoproliferative disorder after paediatric liver transplantation.
Liu Y, Sun LY, Zhu ZJ, Wei L, Qu W, Wang L, Yuan LL, Zeng ZG
Int J Clin Pract 2021 Apr;75(4):e13843. Epub 2020 Dec 14 doi: 10.1111/ijcp.13843. PMID: 33222369
Treatment and outcomes in classic Hodgkin lymphoma post-transplant lymphoproliferative disorder in children.
Twist CJ, Hiniker SM, Gratzinger D, Gutkin PM, Merriott DJ, Iagaru A, Link MP, Donaldson SS
Pediatr Blood Cancer 2019 Aug;66(8):e27803. Epub 2019 May 7 doi: 10.1002/pbc.27803. PMID: 31062898
Post-transplant lymphoproliferative disorders.
Singavi AK, Harrington AM, Fenske TS
Cancer Treat Res 2015;165:305-27. doi: 10.1007/978-3-319-13150-4_13. PMID: 25655616
Successful treatment of a classic Hodgkin lymphoma-type post-transplant lymphoproliferative disorder with tailored chemotherapy and Epstein-Barr virus-specific cytotoxic T lymphocytes in a pediatric heart transplant recipient.
Basso S, Zecca M, Calafiore L, Rubert L, Fiocchi R, Paulli M, Quartuccio G, Guido I, Sebastiani R, Croci GA, Beschi C, Nardiello I, Ginevri F, Cugno C, Comoli P
Pediatr Transplant 2013 Nov;17(7):E168-73. Epub 2013 Sep 1 doi: 10.1111/petr.12146. PMID: 23992468

Prognosis

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.
Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Casadei B, Bond DA, Jaglowski S, Spinner MA, Arai S, Lowsky R, Shah GL, Perales MA, De Colella JMS, Blaise D, Herrera AF, Shouse G, Spilleboudt C, Ansell SM, Nieto Y, Badar T, Hamadani M, Feldman TA, Dahncke L, Singh AK, McGuirk JP, Nishihori T, Chavez J, Serritella AV, Kline J, Mohty M, Dulery R, Stamatoulas A, Houot R, Manson G, Moles-Moreau MP, Orvain C, Bouabdallah K, Modi D, Ramchandren R, Lekakis L, Beitinjaneh A, Frigault MJ, Chen YB, Lynch RC, Smith SD, Rao U, Byrne M, Romancik JT, Cohen JB, Nathan S, Phillips T, Joyce RM, Rahimian M, Bashey A, Ballard HJ, Svoboda J, Torri V, Sollini M, De Philippis C, Magagnoli M, Santoro A, Armand P, Zinzani PL, Carlo-Stella C
Leukemia 2021 Sep;35(9):2672-2683. Epub 2021 Mar 3 doi: 10.1038/s41375-021-01193-6. PMID: 33658659
Treatment and outcomes in classic Hodgkin lymphoma post-transplant lymphoproliferative disorder in children.
Twist CJ, Hiniker SM, Gratzinger D, Gutkin PM, Merriott DJ, Iagaru A, Link MP, Donaldson SS
Pediatr Blood Cancer 2019 Aug;66(8):e27803. Epub 2019 May 7 doi: 10.1002/pbc.27803. PMID: 31062898
Diagnostic, prognostic and therapeutic role of CD30 in lymphoma.
Pierce JM, Mehta A
Expert Rev Hematol 2017 Jan;10(1):29-37. Epub 2016 Dec 21 doi: 10.1080/17474086.2017.1270202. PMID: 27927047
Post-transplant lymphoproliferative disorders.
Singavi AK, Harrington AM, Fenske TS
Cancer Treat Res 2015;165:305-27. doi: 10.1007/978-3-319-13150-4_13. PMID: 25655616
Successful treatment of a classic Hodgkin lymphoma-type post-transplant lymphoproliferative disorder with tailored chemotherapy and Epstein-Barr virus-specific cytotoxic T lymphocytes in a pediatric heart transplant recipient.
Basso S, Zecca M, Calafiore L, Rubert L, Fiocchi R, Paulli M, Quartuccio G, Guido I, Sebastiani R, Croci GA, Beschi C, Nardiello I, Ginevri F, Cugno C, Comoli P
Pediatr Transplant 2013 Nov;17(7):E168-73. Epub 2013 Sep 1 doi: 10.1111/petr.12146. PMID: 23992468

Clinical prediction guides

Epstein-Barr virus latency patterns in polymorphic lymphoproliferative disorders and lymphomas in immunodeficiency settings: Diagnostic implications.
Volaric AK, Saleem A, Younes SF, Zhao S, Natkunam Y
Ann Diagn Pathol 2024 Jun;70:152286. Epub 2024 Feb 29 doi: 10.1016/j.anndiagpath.2024.152286. PMID: 38447253
Epstein-Barr virus-associated risk factors for post-transplant lymphoproliferative disease in pediatric liver transplant recipients.
Quintero Bernabeu J, Juamperez J, Mercadal-Hally M, Larrarte King M, Gallego Melcon S, Gros Subias L, Sábado Álvarez C, Soler-Palacin P, Melendo Pérez S, Esperalba J, Navarro Jiménez A, Garrido Pontnou M, Camacho Soriano J, Hidalgo Llompart E, Bilbao Aguirre I, Charco Torra R
Pediatr Transplant 2022 Sep;26(6):e14292. Epub 2022 Apr 24 doi: 10.1111/petr.14292. PMID: 35466492
Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume.
Yhim HY, Eshet Y, Metser U, Lajkosz K, Cooper M, Prica A, Kukreti V, Bhella S, Lang N, Xu W, Rodin D, Hodgson D, Tsang R, Crump M, Kuruvilla J, Kridel R
Am J Hematol 2022 May;97(5):583-591. Epub 2022 Feb 23 doi: 10.1002/ajh.26500. PMID: 35170780
Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment.
Overkamp M, Granai M, Bonzheim I, Steinhilber J, Schittenhelm J, Bethge W, Quintanilla-Martinez L, Fend F, Federmann B
Virchows Arch 2021 Jun;478(6):1135-1148. Epub 2020 Dec 15 doi: 10.1007/s00428-020-02985-4. PMID: 33324999Free PMC Article
Classical Hodgkin's lymphoma arising in different host's conditions: pathobiology parameters, therapeutic options, and outcome.
Carbone A, Spina M, Gloghini A, Tirelli U
Am J Hematol 2011 Feb;86(2):170-9. doi: 10.1002/ajh.21910. PMID: 21264899

Recent systematic reviews

Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.
Berger GK, McBride A, Lawson S, Royball K, Yun S, Gee K, Bin Riaz I, Saleh AA, Puvvada S, Anwer F
Crit Rev Oncol Hematol 2017 Jan;109:42-50. Epub 2016 Nov 21 doi: 10.1016/j.critrevonc.2016.11.009. PMID: 28010897Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...